rs534438354
Positions:
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 3P and 0B. PM2PP5
The NM_003896.4(ST3GAL5):c.1063G>A(p.Glu355Lys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000198 in 1,614,062 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00011 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000011 ( 0 hom. )
Consequence
ST3GAL5
NM_003896.4 missense
NM_003896.4 missense
Scores
5
11
3
Clinical Significance
Conservation
PhyloP100: 7.79
Genes affected
ST3GAL5 (HGNC:10872): (ST3 beta-galactoside alpha-2,3-sialyltransferase 5) Ganglioside GM3 is known to participate in the induction of cell differentiation, modulation of cell proliferation, maintenance of fibroblast morphology, signal transduction, and integrin-mediated cell adhesion. The protein encoded by this gene is a type II membrane protein which catalyzes the formation of GM3 using lactosylceramide as the substrate. The encoded protein is a member of glycosyltransferase family 29 and may be localized to the Golgi apparatus. Mutation in this gene has been associated with Amish infantile epilepsy syndrome. Transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 3 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 2-85840338-C-T is Pathogenic according to our data. Variant chr2-85840338-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 140575.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=2, Pathogenic=2, Likely_pathogenic=1}. Variant chr2-85840338-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ST3GAL5 | NM_003896.4 | c.1063G>A | p.Glu355Lys | missense_variant | 7/7 | ENST00000638572.2 | NP_003887.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ST3GAL5 | ENST00000638572.2 | c.1063G>A | p.Glu355Lys | missense_variant | 7/7 | 1 | NM_003896.4 | ENSP00000491316.1 |
Frequencies
GnomAD3 genomes AF: 0.000105 AC: 16AN: 152194Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
16
AN:
152194
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251394Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135864
GnomAD3 exomes
AF:
AC:
5
AN:
251394
Hom.:
AF XY:
AC XY:
2
AN XY:
135864
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000109 AC: 16AN: 1461750Hom.: 0 Cov.: 31 AF XY: 0.0000110 AC XY: 8AN XY: 727140
GnomAD4 exome
AF:
AC:
16
AN:
1461750
Hom.:
Cov.:
31
AF XY:
AC XY:
8
AN XY:
727140
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000105 AC: 16AN: 152312Hom.: 0 Cov.: 32 AF XY: 0.000107 AC XY: 8AN XY: 74472
GnomAD4 genome
AF:
AC:
16
AN:
152312
Hom.:
Cov.:
32
AF XY:
AC XY:
8
AN XY:
74472
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
4
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:4Uncertain:2
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
GM3 synthase deficiency Pathogenic:3Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 27, 2020 | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 15, 2014 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 01, 2022 | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 355 of the ST3GAL5 protein (p.Glu355Lys). This variant is present in population databases (rs534438354, gnomAD 0.04%). This missense change has been observed in individual(s) with clinical features of ST3GAL5-related conditions (PMID: 24026681). This variant is also known as c.994G>A, p.E332K. ClinVar contains an entry for this variant (Variation ID: 140575). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects ST3GAL5 function (PMID: 30576498). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 18, 2024 | Variant summary: ST3GAL5 c.1063G>A (p.Glu355Lys), also reported as E332K, results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 251394 control chromosomes. c.1063G>A has been reported in the literature in the homozygous or presumed compound heterozygous states in multiple individuals affected with GM3 synthase deficiency (example, Boccuto_2014, Heide_2022). These data indicate that the variant is likely to be associated with disease. This variant was shown to lack detectable enzymatic activity in vitro and in patient cells (example, Indellicato_2019, Boccuto_2014). The following publications have been ascertained in the context of this evaluation (PMID: 24026681, 34906476, 30576498). ClinVar contains an entry for this variant (Variation ID: 140575). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 08, 2018 | The ST3GAL5 c.1063G>A p.(Glu355Lys) missense variant has been reported in the literature in three siblings of African American ancestry affected with salt and pepper developmental regression syndrome (Boccuto et al. 2014). The p.Glu355Lys variant was absent in 561 normal individuals from the same geographic area (South Carolina), of which 216 were African Americans. The c.1063G>A variant is not observed in version 2.1.1 of the Genome Aggregation Database. Functional studies conducted in patient cells, animal models, in vitro and structural modelling demonstrated that this variant impacts protein function (Boccuto et al. 2014). Based on the collective evidence the c.1063G>A p.(Glu355Lys) variant is classified as pathogenic for salt and pepper developmental regression syndrome. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 16, 2023 | Published functional studies demonstrate that the variant results in loss of enzyme function (Indellicato et al., 2019); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24026681, 35628171, 34906476, 30576498, 36833282) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Uncertain
T
BayesDel_noAF
Uncertain
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Uncertain
T;.;.;.;.;.;.;.;.;.;T;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D;D;.;.;D;D;D;.;.;.;D;D
M_CAP
Benign
D
MetaRNN
Uncertain
D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;.;.;.;.;.;.;.;.;.;.;.
PrimateAI
Uncertain
T
PROVEAN
Uncertain
.;D;D;.;.;.;.;.;.;.;.;.
REVEL
Pathogenic
Sift
Uncertain
.;D;D;.;.;.;.;.;.;.;.;.
Sift4G
Uncertain
.;D;D;.;.;.;.;.;.;.;.;.
Polyphen
D;D;D;D;.;.;.;D;D;D;.;D
Vest4
0.93, 0.93
MutPred
Gain of ubiquitination at E355 (P = 0.0428);.;.;.;.;.;.;.;.;.;.;.;
MVP
0.18
MPC
1.1
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at